Incidence and outcomes of EGFR mutated non-small cell lung cancer treated with surgery: EXERPOS GFPC study. Ann Oncol 2022;33:S7

JB Auliac, Y Simonneau, P Thomas, F Guisier, O Bylicki,  H Curcio, A. Swalduz , M Wislez , M Geier , J Le Treut, C Decroisette, L Falchero, J. Tricard , D. Moreau, E Huchot , G De Chabot , K Leroy, A Lupo Mansuet , C Chouaid, L Greillier.

 

Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019). Ann Oncol 2022;33:S987

C Ricordel,  A .Anota, M Bernardi, L Falchero, JB.Auliac, L Greillier, O Bylick, G De Chabot, A Demaegdt, A Vergnenègre, C Decroisette, I Martel_Lafay, C Chouaid, F Guisier.

 

GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies. Ann Oncol 2022;33:S1018-S1019

O Bylicki, R Gervais, I Monnet, C Ricordel, L Bigay-Game, M Geier, C Decroisette, C Daniel, F Guisier, A Swalduz, AC Toffart, H Doubre, JM Peloni, D Arpin, H Morel, R Veillon, B Clarisse, P-H.Martins-Lavinas, L Greillier C Chouaid.

 

A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017). Ann Oncol 2022;33:S1028-S1029

C.Decroisette, I Monnet, C Ricordel, A Demaegdt, L Falchero, O Bylicki, M Geier, G Justeau, M Bernardi, M Andre, F Guisier, P Fournel, S Vieillot P.A Hauss, R Schott, J Crequit, J. .Auliac, C Chouaid, L.Greillier.

 

Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer. Ann Oncol 2022;33: S1077

S Gendarme, S Zebachi, R Corre, L Greillier, G Justeau, O Bylicki, C Decroisette, JB Auliac, F Guisier, M Geier, C Ricordel, M Frelaut, E Paillaud, C Chouaid, F.Canouï-Poitrine.

 

Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy Ann Oncol 2022;33:S1052

A Bronstein, R Gervais, I Monnet, C Ricordel, L Bigay-Game, M Geier, C. Decroisette, C Daniel, F Guisier, A Swalduz, AC Toffart, H Doubre, JM Peloni, D Arpin, H Morel, R Veillon, B Clarisse, C Chouaid, L. Greillier, O. Bylicki.